Artesunate induces ferroptosis in osteosarcoma through NCOA4-mediated ferritinophagy

Rui Huang1,2, Ruiqing Xu3, Jiandang Shi1

  • 1Department of Orthopedic Surgery, General Hospital of Ningxia Medical University, Yinchuan, China.

Insights

Artesunate (ART) shows potential against osteosarcoma (OS) by inducing ferroptosis, a cell death pathway. ART triggers iron accumulation and lipid peroxidation, inhibiting OS tumor growth in preclinical models.

Area of Science:

  • Oncology
  • Biochemistry
  • Pharmacology

Background:

  • Osteosarcoma (OS) is a primary bone cancer with limited treatment options.
  • Artesunate (ART), known for malaria treatment, exhibits anti-tumor properties.
  • Investigating ART's efficacy and mechanisms against OS is crucial.

Purpose of the Study:

  • To evaluate the anti-osteosarcoma (OS) effects of Artesunate (ART).
  • To elucidate the underlying molecular mechanisms of ART's anti-OS activity, focusing on ferroptosis.
  • To assess ART's therapeutic potential in an in vivo OS xenograft model.

Main Methods:

  • RNA sequencing, iron accumulation assays, lipid peroxidation analysis, western blotting, and siRNA transfection were employed.
  • Cellular assays assessed proliferation, glutathione/glutathione disulfide (GSH/GSSG) ratio, and protein expression (xCT, GPX4, TFR, DMT1, NCOA4).
  • An in vivo xenograft mouse model was used to evaluate ART's anti-tumor efficacy.

Main Results:

  • ART significantly inhibited OS cell proliferation and tumor growth in vivo.
  • ART induced ferroptosis by decreasing GSH/GSSG ratio and xCT/GPX4 expression, while increasing lipid peroxidation (MDA).
  • ART upregulated transferrin receptor (TFR) and DMT1, triggering NCOA4-mediated ferritinophagy, leading to iron overload and ferroptosis.

Conclusions:

  • Artesunate (ART) demonstrates significant anti-osteosarcoma (OS) potential.
  • ART exerts its anti-tumor effects primarily through the induction of ferroptosis via NCOA4-mediated ferritinophagy.
  • ART represents a promising therapeutic agent for osteosarcoma (OS) treatment.